Targeted delivery of doxorubicin to HER2 positive tumor models

References

• Hood JL. Post isolation modification of exosomes for nanomedicine applications. Nanomedicine. 2016;11(13):1745–1756. doi:10.2217/nnm-2016-010227348448
   PubMed Web of Science ®Google Scholar
• Zhao W, Song Zhuang X-RQ. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine. 2011;6:3087. doi:10.2147/IJN.S2564622163162
   PubMed Web of Science ®Google Scholar
• Zhao J, Xie P, Ye C, et al. Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application. Chem Eng J. 2018;351:157–168. doi:10.1016/j.cej.2018.06.101
   Web of Science ®Google Scholar
• Yang H, Zhao J, Wu C, Ye C, Zou D, Wang S. Facile synthesis of colloidal stable MoS2 nanoparticles for combined tumor therapy. Chem Eng J. 2018;351:548–558. doi:10.1016/j.cej.2018.06.100
   Web of Science ®Google Scholar
• Guo B, Zhao J, Wu C, et al. One-pot synthesis of polypyrrole nanoparticles with tunable photothermal conversion and drug loading capacity. Colloids Surf B Biointerfaces. 2019;177:346–355. doi:10.1016/j.colsurfb.2019.02.01630772669
   PubMedGoogle Scholar
• Yang Y, Chen Y, Zhang F, Zhao Q, Zhong H. Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress. Int J Hyperthermia. 2015;31(5):498–506. doi:10.3109/02656736.2015.103638425955015
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta Rev Cancer. 2014;1846(1):75–87. doi:10.1016/j.bbcan.2014.04.005
   PubMed Web of Science ®Google Scholar
• Yuan Z, Kolluri KK, Gowers KH, Janes SM. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy. J Extracell Vesicles. 2017;6(1):1265291. doi:10.1080/20013078.2017.126529128326166
   PubMedGoogle Scholar
• Klopp AH, Spaeth EL, Dembinski JL, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007;67(24):11687–11695. doi:10.1158/0008-5472.CAN-07-140618089798
   PubMed Web of Science ®Google Scholar
• Khodashenas Limoni S, Salimi F, Forouzandeh Moghaddam M. Designing pLEX-LAMP-DARPin lentiviral vector for exression of HER2 targeted DARPin on exosome surface. J Mazandaran Univ Med Sci. 2017;27(151):12–23.
   Google Scholar
• Limoni SK, Moghadam MF, Moazzeni SM, Gomari H, Salimi F. Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells. #ABAB-D-18-00049R1, ed Appl Biochem Biotechnol. 2019;187(1):352–364. doi:10.1007/s12010-018-2813-4
   Web of Science ®Google Scholar
• Gomari H, Moghadam MF, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco Targets Ther. 2018;11:5753–5762. doi:10.2147/OTT30254468
   PubMed Web of Science ®Google Scholar
• Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD nanoparticles. Nanomedicine. 2012;8(5):692–701. doi:10.1016/j.nano.2011.09.01022024191
   PubMed Web of Science ®Google Scholar
• Razazan A, Behravan J, Arab A, et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS One. 2017;12(10):e0185099. doi:10.1371/journal.pone.018509929045460
   PubMed Web of Science ®Google Scholar
• Escrevente C, Keller S, Altevogt P, Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011;11(1):108. doi:10.1186/1471-2407-11-10821439085
   PubMed Web of Science ®Google Scholar
• Tian Y, Li S, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–2390. doi:10.1016/j.biomaterials.2013.11.08324345736
   PubMed Web of Science ®Google Scholar
• Tan CY, Lai RC, Wong W, Dan YY, Lim S-K, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014;5(3):76. doi:10.1186/scrt46524915963
   PubMed Web of Science ®Google Scholar
• Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655–664. doi:10.1016/j.nano.2015.10.01226586551
   PubMed Web of Science ®Google Scholar
• Li W, Mu D, Tian F, et al. Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity. Mol Med Rep. 2013;8(6):1876–1882. doi:10.3892/mmr.2013.173824146068
   PubMedGoogle Scholar
• Bellavia D, Raimondo S, Calabrese G, et al. Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics. 2017;7(5):1333. doi:10.7150/thno.1709228435469
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Chiodoni C, Squarcina P, et al. TNF-related apoptosis-inducing ligand (TRAIL)–armed exosomes deliver proapoptotic signals to tumor site. Clin Cancer Res. 2016;22(14):3499–3512. doi:10.1158/1078-0432.CCR-15-217026944067
   PubMed Web of Science ®Google Scholar
• Antimisiaris S, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10(4):218. doi:10.3390/pharmaceutics10040218
   PubMed Web of Science ®Google Scholar
• Hadla M, Palazzolo S, Corona G, et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. Nanomedicine. 2016;11(18):2431–2441. doi:10.2217/nnm-2016-015427558906
   PubMed Web of Science ®Google Scholar
• Rudnick-Glick S, Corem-Salkmon E, Grinberg I, Margel S. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly (ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model. J Nanobiotechnology. 2016;14(1):80. doi:10.1186/s12951-016-0160-627919267
   PubMedGoogle Scholar
• MacDiarmid JA, Langova V, Bailey D, et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One. 2016;11(4):e0151832. doi:10.1371/journal.pone.015183227050167
   PubMed Web of Science ®Google Scholar
• Toffoli G, Hadla M, Corona G, et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine. 2015;10(19):2963–2971. doi:10.2217/nnm.15.11826420143
   PubMed Web of Science ®Google Scholar
• Ohno SI, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21(1):185–191. doi:10.1038/mt.2012.18023032975
   PubMed Web of Science ®Google Scholar
• Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18(2):160–170. doi:10.1016/j.ccr.2010.06.01420708157
   PubMed Web of Science ®Google Scholar
• Rovero S, Amici A, Di Carlo E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol. 2000;165(9):5133–5142. doi:10.4049/jimmunol.165.9.513311046045
   PubMed Web of Science ®Google Scholar
• Pierpaoli E, Viola V, Barucca A, Orlando F, Galli F, Provinciali M. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice. Carcinogenesis. 2013;34(6):1352–1360. doi:10.1093/carcin/bgt06423430951
   PubMed Web of Science ®Google Scholar